

POST-APPROVAL STUDY RATIONALE

The Sponsor has proposed a Post-Approval Study (PAS) to measure

The PAS is summarized as follows:

Summary of Proposed Post-Approval Study

Title:	“A Post-Approval Study to Assess [REDACTED] [REDACTED] in Subjects Undergoing First-Time Lumbar Spine Surgery”
Indication:	Oxiplex is indicated as a surgical adjuvant during posterior lumbar laminectomy, laminotomy, or discectomy to improve patient outcomes by reducing postoperative leg pain, back pain and neurological symptoms.
Approved Device:	Oxiplex Intraoperative Gel
Administration of Oxiplex:	Coat the dura and exiting nerve root along both its dorsal and ventral surfaces. Apply the gel into the site of the laminectomy/laminotomy to fill depth of the surgical site to the level of the ventral surface of the vertebral lamina. The volume delivered is not to exceed [REDACTED].
a. Background:	<p>Oxiplex is an absorbable, clear, viscoelastic gel that is applied during lumbar spine surgery, immediately prior to closure. Oxiplex is easily placed around exposed tissues (e.g., nerve root and dura). The device remains at the site of application for a period of time, providing a protective environment and physical separation of tissues during the healing process. Oxiplex then clears from the body and does not require a second operation for removal.</p> <p>A pivotal clinical study entitled, “Randomized, Third-Party Blinded, Multicenter, Clinical Trial to Determine the Safety and Effectiveness of Oxiplex/SP Gel for the Reduction of Pain and Symptoms Following Lumbar Disc Surgery,” (“Pivotal Study”) was carried out under IDE G000226 (FzioMed, Inc. Clinical Protocol FZ-SP002).</p> <p>The study design was a multicenter, randomized, third-party blinded parallel group study. This was a superiority study. All subjects underwent lumbar disc surgery. Subjects were randomized to receive surgery plus Oxiplex/SP Gel (the Oxiplex group) or to receive surgery only (the Control group). Randomization occurred intraoperatively, immediately prior to wound closure. Subjects were not considered to be enrolled until they had met all eligibility criteria (preoperative and intraoperative), were randomized, and had received a study group assignment and subject identification number.</p> <p>There were 352 subjects enrolled at 29 investigational sites resulting in 334</p>

	<p>subjects who reported [REDACTED]</p> <p>There were no clinical differences in the number of subjects having adverse events (AEs) or serious adverse events (SAEs) between the Oxiplex and Control groups. There were no AEs leading to discontinuation of any subject from the Pivotal Study or discontinuation of the Pivotal Study. One (1) reoperation occurred in the Oxiplex group, while six (6) reoperations occurred in the Control group. There were no clinical differences between the Oxiplex group and the Control group with respect to any of the laboratory tests. Taken together, there were no safety issues identified in the pivotal study.</p> <p>All subjects were treated surgically and showed substantial improvement as a result of surgery. For each subject and for each follow-up evaluation period, measures were derived from the subjects' responses to the Lumbar Spine Outcomes Questionnaire (LSOQ): two pain severity measures (leg and back), leg weakness, physical symptoms, subject satisfaction, disability days, and activities of daily living.</p> <p>Across all seven effectiveness measures, subjects in the Oxiplex group had greater mean differences in improvement than the Control group, demonstrating consistent clinical benefit from the use Oxiplex.</p> <p>[REDACTED]</p>
b. Objectives and Study Hypothesis:	<p>The objective of this post-approval study is to confirm [REDACTED] [REDACTED] in subjects who receive Oxiplex during lumbar disc surgery.</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
c. Study Design:	<p>Multicenter, post-approval study to evaluate [REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>Subjects are not considered to be enrolled in the study until all of the following have been met:</p> <ul style="list-style-type: none">All preoperative eligibility criteria have been confirmedInformed consent has been obtainedAll intraoperative eligibility criteria have been confirmedOxiplex has been applied to the surgical site as described belowSubject ID numbers will be assigned in sequential order according to site-specific assignment <p>The site will notify FzioMed of subject enrollment and, following notification, the subject-specific post-operative follow-up forms will be sent [REDACTED] subjects are to receive Oxiplex.</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
d. Study Population, Patient Inclusion and Exclusion Criteria:	<p>Patient Inclusion Criteria</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>

	[Redacted]
<p>f. Study Power and Sample Size Calculations (based on study hypothesis):</p>	[Redacted]
<p>g. Sampling and Recruitment Strategy:</p>	<p><u>Oxiplex-group:</u> [Redacted]</p> <p>[Redacted]</p> <p><u>Control group</u> [Redacted]</p> <p><u>Recruitment:</u> [Redacted].</p>
<p>h. Definitions of Study Endpoints:</p>	<p>1. Safety Endpoints</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>2. Efficacy Endpoint</p> <p>[Redacted]</p> <p>[Redacted]</p>
<p>i. Data Collection Techniques and Quality Assurance and Control:</p>	<p><u>Study site personnel:</u> [Redacted]</p> <p>[Redacted]</p>

	<p>[REDACTED]</p> <p>Subjects may withdraw consent at any time. If consent is withdrawn, it will be documented.</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
k. Analysis Plan:	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
l. Reporting Requirements:	<p>[REDACTED]</p>

m. Timeline:	
n. Sponsor:	<p>FzioMed, Inc., San Luis Obispo, CA (805) 546-0610</p> <p></p> <p></p> <p></p>

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]